Relevance: GS III (Science & Technology – Biotechnology & Health) | Source: The Hindu 

1. What Just Happened?

Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary medical treatment. Doctors extract a patient’s own immune cells (T-cells), genetically train them in a lab to hunt cancer, and put them back into the body.

• The Success and Failure: While this therapy has miraculously cured blood cancers (like leukemia), it has historically failed to defeat solid tumours (like kidney, lung, or ovarian cancer).
• The Breakthrough: A new study published in the journal Science reveals a breakthrough technique using highly sensitive engineered cells that can finally detect and destroy solid tumours.

2. The Core Problem: Why Did it Fail Before?

The main obstacle with solid tumours is Antigen Heterogeneity (think of it as a patchwork).

• The “Hide and Seek” Problem: Cancer cells have specific proteins (antigens) on their surface that act like targets. In a solid tumour, some cancer cells display these targets brightly (visible), while others hide them (invisible).
• The Relapse: Traditional CAR-T cells act like guided missiles that only lock onto the “visible” cells. The “invisible” cells survive the attack, allowing the tumour to silently grow back.

3. The Scientific Solution (The HIT Receptor)

Researchers found that the “invisible” cancer cells were using a specific enzyme to tighten their DNA, effectively dimming the target signal (a protein called CD70) so that normal immune cells could not detect them.

• The New Weapon: To combat this, scientists developed a new type of radar called an HLA-independent T-cell (HIT) receptor.
• How it Works: Instead of just trying to make the CAR-T cell stronger, they wired this new HIT receptor directly into the T-cell’s natural biological engine. This made the cells hypersensitive, allowing them to detect and destroy cancer cells that were previously hiding in the dark.

4. The Safety Challenge (The “Goldilocks” Rule)

In immunology, if you make killer cells too sensitive, you create a massive safety risk.

• The Risk of Toxicity: Hypersensitive T-cells might get confused and start attacking healthy, normal organs that naturally carry very tiny amounts of the same protein.
• The Safeguard: For human trials, scientists are engineering “molecular switches” into these new T-cells. If the immune cells start attacking healthy tissue, doctors can trigger the switch to instantly turn the T-cells off.

5. Why This Matters to India (Administrative Focus)

The transition from treating liquid (blood) cancers to solid tumours is a watershed moment.

• The Cancer Burden: Solid tumours (like breast, lung, cervical, and oral cancers) make up the vast majority of India’s cancer burden.
• India’s Recent Triumph: India’s drug regulator recently approved NexCAR19, the country’s first indigenous CAR-T cell therapy developed by IIT Bombay and Tata Memorial Hospital. This brilliant innovation brought the cost of therapy down from ₹4 crores (abroad) to roughly ₹40 lakhs.
• The Way Forward: Currently, NexCAR19 is only for blood cancers. India’s biotechnology administration must aggressively use this new “HIT receptor” research to expand our indigenous capabilities so we can treat solid tumours affordably for the Indian masses.

UPSC Value Box

Formal Term / Body	Simple Meaning
CAR-T Cell Therapy	Chimeric Antigen Receptor T-cell therapy. Extracting a patient’s immune cells, genetically reprogramming them to hunt cancer, and putting them back in.
NexCAR19	India’s first home-grown CAR-T therapy, which drastically reduced the cost of blood cancer treatment.
Antigen Heterogeneity	The patchwork nature of a tumour where some cells brightly display target proteins, while others hide them to survive immune attacks.
Precision Medicine	Advanced medical care customized to the specific genetic makeup of an individual patient’s tumor.

With reference to advanced biotechnological interventions and cancer treatments in India, consider the following statements:

1. CAR-T cell therapy involves the genetic modification of a patient’s own immune cells to recognize and destroy specific cancer cells.
2. NexCAR19, India’s first indigenous CAR-T cell therapy, was developed primarily for the targeted treatment of solid tumours such as pancreatic and ovarian cancers.
3. The Indian Council of Medical Research (ICMR) provides national guidelines for gene therapy product development and clinical trials in India.

Which of the statements given above is/are correct?

(a) 1 and 2 only

(b) 1 and 3 only

(c) 2 and 3 only

(d) 1, 2 and 3

Correct Answer: (b)